Biogen sues Teva over MS generic
18-03-2021
Fed Circ panel reviews $235m GSK award over ‘skinny’ Teva generic
25-02-2021
nitpicker / Shutterstock.com
The English High Court has found that a challenged claim of Bayer's targeted cancer drug sorafenib is invalid due to obviousness, in a win for Israeli pharmaceutical company Teva Pharmaceuticals.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Bayer, Teva Pharmaceuticals, sorafenib, cancer treatment, tosylate salt, unpatentable, obviousness, prior art, inventive step, patent invalidation
